Next Article in Journal
In Vitro Antibacterial Activity and Mechanism of Vanillic Acid against Carbapenem-Resistant Enterobacter cloacae
Next Article in Special Issue
Ceftazidime–Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections
Previous Article in Journal
Hibiscus Acid and Chromatographic Fractions from Hibiscus Sabdariffa Calyces: Antimicrobial Activity against Multidrug-Resistant Pathogenic Bacteria
Previous Article in Special Issue
Phenylboronic Acids Probing Molecular Recognition against Class A and Class C β-lactamases
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.
Brief Report

Novel β-Lactam/β-Lactamase Combination Versus Meropenem for Treating Nosocomial Pneumonia

1
Department of Orthopedic, Chi Mei Medical Center, Tainan 71004, Taiwan
2
Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch 71051, Tainan, Taiwan
3
Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying 73657, Taiwan
*
Author to whom correspondence should be addressed.
Received: 15 October 2019 / Revised: 6 November 2019 / Accepted: 11 November 2019 / Published: 13 November 2019
This study reports the integrated analysis of two phase III studies of novel β-lactam/β-lactamase combination versus meropenem for treating nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP). The ASPECT-NP trial compared the efficacy and safety of ceftolozane–tazobactam versus meropenem for treating NP/VAP. The REPROVE trial compared ceftazidime–avibactam and meropenem in the treatment of NP/VAP. A total of 1528 patients (361 in the ceftolozane–tazobactam group; 405 in the ceftazidime–avibactam group; 762 in the meropenem group) were analyzed. The clinical cure rates at test-of-cure among the novel β-lactam/β-lactamase combinations group were non-inferior to those of the meropenem (70.7% vs. 72.1%, risk difference (RD) −0.01, 95% confidence interval (CI) 0.06–0.05) in the clinical evaluable populations. Overall 28-day mortality did not differ between novel β-lactam/β-lactamase combinations and the meropenem group (RD, −0.02, 95% CI, −0.09 to 0.05). Regarding the microbiological eradication rate, novel β-lactam/β-lactamase combinations were non-inferior to meropenem for Pseudomonas aeruginosa, Klebsiella pneumoniae, Proteus mirabilis, Haemophilus influenzae, Staphylococcus marcescens, and Enterobacter cloacae. Finally, novel β-lactam/β-lactamase combinations had a similar risk of (i) treatment-emergent adverse events (RD, 0.02, 95% CI, −0.02 to 0.06), (ii) events leading to the discontinuation of the study drug (RD, 0.00, 95% CI, −0.02 to 0.03), (iii) severe adverse events (RD, 0.03, 95% CI, −0.01 to 0.07), and (iv) death (RD, 0.02, 95% CI, −0.02 to 0.05) when compared with meropenem group. In conclusion, our findings suggest that novel β-lactam/β-lactamase combinations of ceftolozane−tazobactam and ceftazidime–avibactam can be recommended as one of the therapeutic options in the treatment of NP/VAP. View Full-Text
Keywords: novel β-lactam/β-lactamase combinations; ceftolozane–tazobactam; ceftazidime–avibactam; nosocomial pneumonia; ventilator-associated pneumonia novel β-lactam/β-lactamase combinations; ceftolozane–tazobactam; ceftazidime–avibactam; nosocomial pneumonia; ventilator-associated pneumonia
Show Figures

Figure 1

MDPI and ACS Style

Lin, W.-T.; Lai, C.-C.; Cheong, C.-U. Novel β-Lactam/β-Lactamase Combination Versus Meropenem for Treating Nosocomial Pneumonia. Antibiotics 2019, 8, 219. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics8040219

AMA Style

Lin W-T, Lai C-C, Cheong C-U. Novel β-Lactam/β-Lactamase Combination Versus Meropenem for Treating Nosocomial Pneumonia. Antibiotics. 2019; 8(4):219. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics8040219

Chicago/Turabian Style

Lin, Wei-Ting, Chih-Cheng Lai, and Chong-Un Cheong. 2019. "Novel β-Lactam/β-Lactamase Combination Versus Meropenem for Treating Nosocomial Pneumonia" Antibiotics 8, no. 4: 219. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics8040219

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop